[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(11/03, TUE) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)

 AZ, 'AR분해제·STEAP2 TCE' 등 초기에셋 4개 "중단"
[https://www.biospectator.com/news/view/30260](https://www.biospectator.com/news/view/30260)

 퍼스트바이오, SK바이오팜 등서 "100억 추가 투자유치"
[https://www.biospectator.com/news/view/30281](https://www.biospectator.com/news/view/30281)

 삼성바이오, 글로벌 제약사와 3.24억弗 "CMO 계약" 
[https://www.biospectator.com/news/view/30279](https://www.biospectator.com/news/view/30279)

 갤럭스, 신용보증기금 ‘Pre-ICON’ 선정.."70억 보증지원" 
[https://www.biospectator.com/news/view/30282](https://www.biospectator.com/news/view/30282)

 밤부사, 나스닥 IPO 1.7억弗..면역 'IL-4RαxIL-31' 2b상
[https://www.biospectator.com/news/view/30262](https://www.biospectator.com/news/view/30262)

 GC녹십자, 국민성장펀드서 1700억 자금조달
[https://www.biospectator.com/news/view/30284](https://www.biospectator.com/news/view/30284)

 한미-로슈 '비만 딜', 업계에 던지는 "진짜 메시지는" 
[https://www.biospectator.com/news/view/30273](https://www.biospectator.com/news/view/30273)

 보령, 스카이랩스와 "혈압계 우주의학 적용 연구" MOU
[https://www.biospectator.com/news/view/30286](https://www.biospectator.com/news/view/30286)

 LG화학, 美리듬과 'MC4R 작용제' 라이선스 계약변경
[https://www.biospectator.com/news/view/30287](https://www.biospectator.com/news/view/30287)

 알테오젠, 3Q 매출 1198억·영업익 789억 "역대최대"
[https://www.biospectator.com/news/view/30288](https://www.biospectator.com/news/view/30288)

 노바티스, 바이오아틱과 'BBB' 플랫폼 "계약 종료" 
[https://www.biospectator.com/news/view/30280](https://www.biospectator.com/news/view/30280)

 한미약품, 국내 AI 3社와 '에피데이 챗봇' 구축 MOU
[https://www.biospectator.com/news/view/30275](https://www.biospectator.com/news/view/30275)

[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(11/03, TUE) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)